Literature DB >> 1320634

Predominance of serum antibodies to synthetic peptide stemming from HPV 18 open reading frame E2 in cervical adenocarcinoma.

M Lehtinen1, A Leminen, J Paavonen, P Lehtovirta, H Hyöty, E Vesterinen, J Dillner.   

Abstract

AIMS: To determine if there are type specific differences in serum antibody responses to synthetic peptides derived from human papillomavirus (HPV) open reading frame (ORF) E2 in patients with cervical carcinoma.
METHODS: Diagnostic phase sera from 88 age-matched women with cervical adenocarcinoma (AC), cervical squamous cell carcinoma (SC), ovarian cancer (OC) or no gynaecological malignancy were available. Serum IgG and IgA antibodies to synthetic peptides corresponding to a residue of HPV 6, 11, 16, and 18 ORF E2 18 amino acids long and a control peptide from mumps virus were determined by ELISA.
RESULTS: Both IgA and IgG antibody positivity to the HPV 18 peptide were associated with increased risk (9.0-fold, confidence limits 1.5-199) for AC. IgA positivity to HPV 11, 16, and 18 peptides was associated with an increased risk for SC. However, the association of IgG antibodies to HPV 16 peptide with SC was not significant. IgA or IgG antibodies to HPV 6 or mumps virus peptides were not associated with increased risk for AC, SC, or OC.
CONCLUSIONS: These results suggest a specific role for HPV 18 in AC. Differences in antibody responses to HPV peptide in AC and SC suggest immunopathogenetic differences between the two types of cervical carcinoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320634      PMCID: PMC495222          DOI: 10.1136/jcp.45.6.494

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  17 in total

1.  Histogenesis of cervical adenocarcinoma with reference to human papillomavirus-18 as a carcinogen.

Authors:  T Okagaki; T Tase; L B Twiggs; L F Carson
Journal:  J Reprod Med       Date:  1989-09       Impact factor: 0.142

2.  Identification of the human papillomavirus E2 protein in genital tract tissues.

Authors:  C C Li; R V Gilden; S D Showalter; K V Shah
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

3.  Occurrence of antibodies to L1, L2, E4 and E7 gene products of human papillomavirus types 6b, 16 and 18 among cervical cancer patients and controls.

Authors:  H G Köchel; M Monazahian; K Sievert; M Höhne; C Thomssen; A Teichmann; P Arendt; R Thomssen
Journal:  Int J Cancer       Date:  1991-07-09       Impact factor: 7.396

4.  A synthetic peptide defines a serologic IgA response to a human papillomavirus-encoded nuclear antigen expressed in virus-carrying cervical neoplasia.

Authors:  J Dillner; L Dillner; J Robb; J Willems; I Jones; W Lancaster; R Smith; R Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

5.  Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls.

Authors:  V M Mann; S L de Lao; M Brenes; L A Brinton; J A Rawls; M Green; W C Reeves; W E Rawls
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

6.  Topography of early HPV 16 transcription in high-grade genital precancers.

Authors:  C P Crum; M Symbula; B E Ward
Journal:  Am J Pathol       Date:  1989-06       Impact factor: 4.307

7.  Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm.

Authors:  A P Cullen; R Reid; M Campion; A T Lörincz
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

8.  Human papillomavirus types 16 and 18 in adenocarcinoma of the uterine cervix.

Authors:  A Leminen; J Paavonen; E Vesterinen; T Wahlström; I Rantala; M Lehtinen
Journal:  Am J Clin Pathol       Date:  1991-05       Impact factor: 2.493

9.  Absence of human papilloma virus in cervical adenocarcinoma determined by in situ hybridisation.

Authors:  F I Young; L M Ward; L J Brown
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

10.  DNA sequence and genome organization of genital human papillomavirus type 6b.

Authors:  E Schwarz; M Dürst; C Demankowski; O Lattermann; R Zech; E Wolfsperger; S Suhai; H zur Hausen
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  2 in total

1.  Antibodies against papillomavirus antigens in cervical secretions from condyloma patients.

Authors:  L Dillner; A Fredriksson; E Persson; O Forslund; B G Hansson; J Dillner
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

2.  Differences in serological IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia.

Authors:  L Rocha-Zavaleta; D Jordan; S Pepper; G Corbitt; F Clarke; N J Maitland; C M Sanders; J R Arrand; P L Stern; S N Stacey
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.